ABP1011T

Phase I: Primary purpose: To evaluate the safety and tolerability of ABP1011T tablets in patients with advanced malignant solid tumors; to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended dose (RP2D) for Phase II clinical trials and dosing regimen. Secondary purpose: 1) To study the pharmacokinetic (PK) characteristics of single and multiple doses of ABP1011T tablets in patients with advanced malignant solid tumors. 2) To preliminarily evaluate the effectiveness of ABP1011T tablets in the treatment of advanced malignant solid tumors. Phase II: Primary purpose: To preliminarily evaluate the effectiveness of ABP1011T tablets in target patients with advanced malignant solid tumors. Secondary purpose: 1) To preliminarily evaluate the effectiveness of ABP1011T tablets in target patients with advanced malignant solid tumors. 2) To evaluate the safety and tolerability of ABP1011T tablets in target patients with advanced malignant solid tumors.